#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1. Introduction
1-1	0-2	1.	_	_	_	_
1-2	3-15	Introduction	abstract	new	_	_

#Text=The increasing resistances of pathogenic bacteria are one great problem for worldwide health policy , because it means a threat of humanity .
2-1	16-19	The	abstract[2]	new[2]	coref	2-8[4_2]
2-2	20-30	increasing	abstract[2]	new[2]	_	_
2-3	31-42	resistances	abstract[2]	new[2]	_	_
2-4	43-45	of	abstract[2]	new[2]	_	_
2-5	46-56	pathogenic	abstract[2]|animal[3]	new[2]|new[3]	coref	3-1[10_3]
2-6	57-65	bacteria	abstract[2]|animal[3]	new[2]|new[3]	_	_
2-7	66-69	are	_	_	_	_
2-8	70-73	one	abstract[4]	giv[4]	coref	9-18[48_4]
2-9	74-79	great	abstract[4]	giv[4]	_	_
2-10	80-87	problem	abstract[4]	giv[4]	_	_
2-11	88-91	for	abstract[4]	giv[4]	_	_
2-12	92-101	worldwide	abstract[4]|abstract[6]	giv[4]|new[6]	ana	2-17[0_6]
2-13	102-108	health	abstract[4]|abstract|abstract[6]	giv[4]|new|new[6]	_	_
2-14	109-115	policy	abstract[4]|abstract[6]	giv[4]|new[6]	_	_
2-15	116-117	,	_	_	_	_
2-16	118-125	because	_	_	_	_
2-17	126-128	it	abstract	giv	_	_
2-18	129-134	means	_	_	_	_
2-19	135-136	a	abstract[8]	new[8]	_	_
2-20	137-143	threat	abstract[8]	new[8]	_	_
2-21	144-146	of	abstract[8]	new[8]	_	_
2-22	147-155	humanity	abstract[8]|abstract	new[8]|new	_	_
2-23	156-157	.	_	_	_	_

#Text=Pathogenic bacteria can be found in human surroundings , and drinking water may be contaminated with bacteria in developing countries .
3-1	158-168	Pathogenic	animal[10]	giv[10]	coref	3-17[0_10]
3-2	169-177	bacteria	animal[10]	giv[10]	_	_
3-3	178-181	can	_	_	_	_
3-4	182-184	be	_	_	_	_
3-5	185-190	found	_	_	_	_
3-6	191-193	in	_	_	_	_
3-7	194-199	human	place[11]	new[11]	_	_
3-8	200-212	surroundings	place[11]	new[11]	_	_
3-9	213-214	,	_	_	_	_
3-10	215-218	and	_	_	_	_
3-11	219-227	drinking	substance[12]	new[12]	_	_
3-12	228-233	water	substance[12]	new[12]	_	_
3-13	234-237	may	_	_	_	_
3-14	238-240	be	_	_	_	_
3-15	241-253	contaminated	_	_	_	_
3-16	254-258	with	_	_	_	_
3-17	259-267	bacteria	animal	giv	coref	4-14[18_0]
3-18	268-270	in	_	_	_	_
3-19	271-281	developing	place[14]	new[14]	coref	12-13[60_14]
3-20	282-291	countries	place[14]	new[14]	_	_
3-21	292-293	.	_	_	_	_

#Text=In the last century sufficient antibacterials were available to effectively treat infections with those various bacteria .
4-1	294-296	In	_	_	_	_
4-2	297-300	the	time[15]	new[15]	_	_
4-3	301-305	last	time[15]	new[15]	_	_
4-4	306-313	century	time[15]	new[15]	_	_
4-5	314-324	sufficient	substance[16]	new[16]	coref	5-2[19_16]
4-6	325-339	antibacterials	substance[16]	new[16]	_	_
4-7	340-344	were	_	_	_	_
4-8	345-354	available	_	_	_	_
4-9	355-357	to	_	_	_	_
4-10	358-369	effectively	_	_	_	_
4-11	370-375	treat	_	_	_	_
4-12	376-386	infections	abstract[17]	new[17]	coref	7-5[33_17]
4-13	387-391	with	abstract[17]	new[17]	_	_
4-14	392-397	those	abstract[17]|animal[18]	new[17]|giv[18]	coref	6-20[31_18]
4-15	398-405	various	abstract[17]|animal[18]	new[17]|giv[18]	_	_
4-16	406-414	bacteria	abstract[17]|animal[18]	new[17]|giv[18]	_	_
4-17	415-416	.	_	_	_	_

#Text=Beside the standard antibacterials like penicillin , reserve antibiotics have been discovered from natural sources and were resynthesized by industrial companies .
5-1	417-423	Beside	_	_	_	_
5-2	424-427	the	substance[19]	giv[19]	coref	23-1[122_19]
5-3	428-436	standard	substance[19]	giv[19]	_	_
5-4	437-451	antibacterials	substance[19]	giv[19]	_	_
5-5	452-456	like	substance[19]	giv[19]	_	_
5-6	457-467	penicillin	substance[19]|substance	giv[19]|new	_	_
5-7	468-469	,	_	_	_	_
5-8	470-477	reserve	place|substance[22]	new|new[22]	coref|coref	6-8[27_22]|8-14
5-9	478-489	antibiotics	substance[22]	new[22]	_	_
5-10	490-494	have	_	_	_	_
5-11	495-499	been	_	_	_	_
5-12	500-510	discovered	_	_	_	_
5-13	511-515	from	_	_	_	_
5-14	516-523	natural	substance[23]	new[23]	coref	20-1[105_23]
5-15	524-531	sources	substance[23]	new[23]	_	_
5-16	532-535	and	_	_	_	_
5-17	536-540	were	_	_	_	_
5-18	541-554	resynthesized	_	_	_	_
5-19	555-557	by	_	_	_	_
5-20	558-568	industrial	organization[24]	new[24]	coref	14-15[73_24]
5-21	569-578	companies	organization[24]	new[24]	_	_
5-22	579-580	.	_	_	_	_

#Text=However , an abuse and overuse of those antibiotics is one of the reasons for the present crisis with resistant bacteria .
6-1	581-588	However	_	_	_	_
6-2	589-590	,	_	_	_	_
6-3	591-593	an	event[25]	new[25]	_	_
6-4	594-599	abuse	event[25]	new[25]	_	_
6-5	600-603	and	_	_	_	_
6-6	604-611	overuse	organization[26]	new[26]	_	_
6-7	612-614	of	organization[26]	new[26]	_	_
6-8	615-620	those	organization[26]|substance[27]	new[26]|giv[27]	coref	7-8[0_27]
6-9	621-632	antibiotics	organization[26]|substance[27]	new[26]|giv[27]	_	_
6-10	633-635	is	_	_	_	_
6-11	636-639	one	abstract[28]	new[28]	_	_
6-12	640-642	of	abstract[28]	new[28]	_	_
6-13	643-646	the	abstract[28]|abstract[29]	new[28]|new[29]	_	_
6-14	647-654	reasons	abstract[28]|abstract[29]	new[28]|new[29]	_	_
6-15	655-658	for	abstract[28]|abstract[29]	new[28]|new[29]	_	_
6-16	659-662	the	abstract[28]|abstract[29]|abstract[30]	new[28]|new[29]|new[30]	coref	14-7[71_30]
6-17	663-670	present	abstract[28]|abstract[29]|abstract[30]	new[28]|new[29]|new[30]	_	_
6-18	671-677	crisis	abstract[28]|abstract[29]|abstract[30]	new[28]|new[29]|new[30]	_	_
6-19	678-682	with	abstract[28]|abstract[29]|abstract[30]	new[28]|new[29]|new[30]	_	_
6-20	683-692	resistant	abstract[28]|abstract[29]|abstract[30]|animal[31]	new[28]|new[29]|new[30]|giv[31]	coref	8-8[0_31]
6-21	693-701	bacteria	abstract[28]|abstract[29]|abstract[30]|animal[31]	new[28]|new[29]|new[30]|giv[31]	_	_
6-22	702-703	.	_	_	_	_

#Text=In the case of viral infections , antibiotics are often prescribed .
7-1	704-706	In	_	_	_	_
7-2	707-710	the	abstract[32]	new[32]	_	_
7-3	711-715	case	abstract[32]	new[32]	_	_
7-4	716-718	of	abstract[32]	new[32]	_	_
7-5	719-724	viral	abstract[32]|abstract[33]	new[32]|giv[33]	_	_
7-6	725-735	infections	abstract[32]|abstract[33]	new[32]|giv[33]	_	_
7-7	736-737	,	_	_	_	_
7-8	738-749	antibiotics	substance	giv	coref	8-10[38_0]
7-9	750-753	are	_	_	_	_
7-10	754-759	often	_	_	_	_
7-11	760-770	prescribed	_	_	_	_
7-12	771-772	.	_	_	_	_

#Text=In the case of existing sensitivities of bacteria towards standard antibiotics , novel reserve antibiotics have been used in clinics .
8-1	773-775	In	_	_	_	_
8-2	776-779	the	abstract[35]	new[35]	_	_
8-3	780-784	case	abstract[35]	new[35]	_	_
8-4	785-787	of	abstract[35]	new[35]	_	_
8-5	788-796	existing	abstract[35]|abstract[36]	new[35]|new[36]	_	_
8-6	797-810	sensitivities	abstract[35]|abstract[36]	new[35]|new[36]	_	_
8-7	811-813	of	abstract[35]|abstract[36]	new[35]|new[36]	_	_
8-8	814-822	bacteria	abstract[35]|abstract[36]|animal	new[35]|new[36]|giv	coref	9-3[42_0]
8-9	823-830	towards	abstract[35]|abstract[36]	new[35]|new[36]	_	_
8-10	831-839	standard	abstract[35]|abstract[36]|substance[38]	new[35]|new[36]|giv[38]	coref	8-13[40_38]
8-11	840-851	antibiotics	abstract[35]|abstract[36]|substance[38]	new[35]|new[36]|giv[38]	_	_
8-12	852-853	,	_	_	_	_
8-13	854-859	novel	substance[40]	giv[40]	coref	9-7[44_40]
8-14	860-867	reserve	place|substance[40]	giv|giv[40]	_	_
8-15	868-879	antibiotics	substance[40]	giv[40]	_	_
8-16	880-884	have	_	_	_	_
8-17	885-889	been	_	_	_	_
8-18	890-894	used	_	_	_	_
8-19	895-897	in	_	_	_	_
8-20	898-905	clinics	place	new	_	_
8-21	906-907	.	_	_	_	_

#Text=Therefore , bacteria with contact to those antibiotics like Staphylococcus aureus on human surfaces like skin developed early resistances .
9-1	908-917	Therefore	_	_	_	_
9-2	918-919	,	_	_	_	_
9-3	920-928	bacteria	animal[42]	giv[42]	coref	13-3[0_42]
9-4	929-933	with	animal[42]	giv[42]	_	_
9-5	934-941	contact	animal[42]|abstract[43]	giv[42]|new[43]	_	_
9-6	942-944	to	animal[42]|abstract[43]	giv[42]|new[43]	_	_
9-7	945-950	those	animal[42]|abstract[43]|substance[44]	giv[42]|new[43]|giv[44]	coref	10-4[0_44]
9-8	951-962	antibiotics	animal[42]|abstract[43]|substance[44]	giv[42]|new[43]|giv[44]	_	_
9-9	963-967	like	animal[42]|abstract[43]|substance[44]	giv[42]|new[43]|giv[44]	_	_
9-10	968-982	Staphylococcus	animal[42]|abstract[43]|substance[44]|animal[45]	giv[42]|new[43]|giv[44]|new[45]	coref	31-19[0_45]
9-11	983-989	aureus	animal[42]|abstract[43]|substance[44]|animal[45]	giv[42]|new[43]|giv[44]|new[45]	_	_
9-12	990-992	on	animal[42]	giv[42]	_	_
9-13	993-998	human	animal[42]|place[46]	giv[42]|new[46]	_	_
9-14	999-1007	surfaces	animal[42]|place[46]	giv[42]|new[46]	_	_
9-15	1008-1012	like	animal[42]|place[46]	giv[42]|new[46]	_	_
9-16	1013-1017	skin	animal[42]|place[46]|object	giv[42]|new[46]|new	_	_
9-17	1018-1027	developed	abstract|event	new|new	none|none|none	9-17[0_75]|13-4|9-17[0_78]
9-18	1028-1033	early	abstract[48]	giv[48]	_	_
9-19	1034-1045	resistances	abstract[48]	giv[48]	_	_
9-20	1046-1047	.	_	_	_	_

#Text=A misuse of antibiotics is also present in the mast of poultry .
10-1	1048-1049	A	event[49]	new[49]	_	_
10-2	1050-1056	misuse	event[49]	new[49]	_	_
10-3	1057-1059	of	event[49]	new[49]	_	_
10-4	1060-1071	antibiotics	event[49]|substance	new[49]|giv	coref	11-1[53_0]
10-5	1072-1074	is	_	_	_	_
10-6	1075-1079	also	_	_	_	_
10-7	1080-1087	present	_	_	_	_
10-8	1088-1090	in	_	_	_	_
10-9	1091-1094	the	object[51]	new[51]	_	_
10-10	1095-1099	mast	object[51]	new[51]	_	_
10-11	1100-1102	of	object[51]	new[51]	_	_
10-12	1103-1110	poultry	object[51]|animal	new[51]|new	_	_
10-13	1111-1112	.	_	_	_	_

#Text=Those antibiotics contaminate the environment by animal excretions .
11-1	1113-1118	Those	substance[53]	giv[53]	coref	14-29[76_53]
11-2	1119-1130	antibiotics	substance[53]	giv[53]	_	_
11-3	1131-1142	contaminate	_	_	_	_
11-4	1143-1146	the	place[54]	new[54]	_	_
11-5	1147-1158	environment	place[54]	new[54]	_	_
11-6	1159-1161	by	_	_	_	_
11-7	1162-1168	animal	animal|event[56]	new|new[56]	_	_
11-8	1169-1179	excretions	event[56]	new[56]	_	_
11-9	1180-1181	.	_	_	_	_

#Text=Finally , industrial waste of antibiotic production is pumped into rivers in producing countries like India .
12-1	1182-1189	Finally	_	_	_	_
12-2	1190-1191	,	_	_	_	_
12-3	1192-1202	industrial	substance[57]	new[57]	_	_
12-4	1203-1208	waste	substance[57]	new[57]	_	_
12-5	1209-1211	of	substance[57]	new[57]	_	_
12-6	1212-1222	antibiotic	substance[57]|abstract[58]	new[57]|new[58]	_	_
12-7	1223-1233	production	substance[57]|abstract[58]	new[57]|new[58]	_	_
12-8	1234-1236	is	_	_	_	_
12-9	1237-1243	pumped	_	_	_	_
12-10	1244-1248	into	_	_	_	_
12-11	1249-1255	rivers	place[59]	new[59]	_	_
12-12	1256-1258	in	place[59]	new[59]	_	_
12-13	1259-1268	producing	place[59]|place[60]	new[59]|giv[60]	coref	16-10[84_60]
12-14	1269-1278	countries	place[59]|place[60]	new[59]|giv[60]	_	_
12-15	1279-1283	like	place[59]|place[60]	new[59]|giv[60]	_	_
12-16	1284-1289	India	place[59]|place[60]|place	new[59]|giv[60]|new	_	_
12-17	1290-1291	.	_	_	_	_

#Text=Moreover , bacteria develop resistance mechanisms that allow the spread of resistance genes via plasmids , and also between different species .
13-1	1292-1300	Moreover	_	_	_	_
13-2	1301-1302	,	_	_	_	_
13-3	1303-1311	bacteria	animal	giv	coref	19-16[102_0]
13-4	1312-1319	develop	abstract|event	new|new	coref|coref	14-26[75_0]|15-5[78_0]
13-5	1320-1330	resistance	abstract|abstract[64]	new|new[64]	coref	13-12
13-6	1331-1341	mechanisms	abstract[64]	new[64]	_	_
13-7	1342-1346	that	abstract[64]	new[64]	_	_
13-8	1347-1352	allow	abstract[64]	new[64]	_	_
13-9	1353-1356	the	abstract[64]|event[65]	new[64]|new[65]	_	_
13-10	1357-1363	spread	abstract[64]|event[65]	new[64]|new[65]	_	_
13-11	1364-1366	of	abstract[64]|event[65]	new[64]|new[65]	_	_
13-12	1367-1377	resistance	abstract[64]|event[65]|abstract|abstract[67]	new[64]|new[65]|giv|new[67]	_	_
13-13	1378-1383	genes	abstract[64]|event[65]|abstract[67]	new[64]|new[65]|new[67]	_	_
13-14	1384-1387	via	abstract[64]|event[65]	new[64]|new[65]	_	_
13-15	1388-1396	plasmids	abstract[64]|event[65]|substance	new[64]|new[65]|new	_	_
13-16	1397-1398	,	_	_	_	_
13-17	1399-1402	and	_	_	_	_
13-18	1403-1407	also	_	_	_	_
13-19	1408-1415	between	_	_	_	_
13-20	1416-1425	different	animal[69]	new[69]	_	_
13-21	1426-1433	species	animal[69]	new[69]	_	_
13-22	1434-1435	.	_	_	_	_

#Text=One other problem that contributes to the present antibiotic crisis is the fact that pharmaceutical companies recently announced that they would no longer invest in the development of novel antibiotics .
14-1	1436-1439	One	abstract[70]	new[70]	coref	14-12[72_70]
14-2	1440-1445	other	abstract[70]	new[70]	_	_
14-3	1446-1453	problem	abstract[70]	new[70]	_	_
14-4	1454-1458	that	abstract[70]	new[70]	_	_
14-5	1459-1470	contributes	abstract[70]	new[70]	_	_
14-6	1471-1473	to	abstract[70]	new[70]	_	_
14-7	1474-1477	the	abstract[70]|abstract[71]	new[70]|giv[71]	_	_
14-8	1478-1485	present	abstract[70]|abstract[71]	new[70]|giv[71]	_	_
14-9	1486-1496	antibiotic	abstract[70]|abstract[71]	new[70]|giv[71]	_	_
14-10	1497-1503	crisis	abstract[70]|abstract[71]	new[70]|giv[71]	_	_
14-11	1504-1506	is	_	_	_	_
14-12	1507-1510	the	abstract[72]	giv[72]	_	_
14-13	1511-1515	fact	abstract[72]	giv[72]	_	_
14-14	1516-1520	that	abstract[72]	giv[72]	_	_
14-15	1521-1535	pharmaceutical	abstract[72]|organization[73]	giv[72]|giv[73]	ana	14-20[0_73]
14-16	1536-1545	companies	abstract[72]|organization[73]	giv[72]|giv[73]	_	_
14-17	1546-1554	recently	abstract[72]	giv[72]	_	_
14-18	1555-1564	announced	abstract[72]	giv[72]	_	_
14-19	1565-1569	that	abstract[72]	giv[72]	_	_
14-20	1570-1574	they	abstract[72]|organization	giv[72]|giv	_	_
14-21	1575-1580	would	abstract[72]	giv[72]	_	_
14-22	1581-1583	no	abstract[72]	giv[72]	_	_
14-23	1584-1590	longer	abstract[72]	giv[72]	_	_
14-24	1591-1597	invest	abstract[72]	giv[72]	_	_
14-25	1598-1600	in	_	_	_	_
14-26	1601-1604	the	abstract[75]	new[75]	_	_
14-27	1605-1616	development	abstract[75]	new[75]	_	_
14-28	1617-1619	of	abstract[75]	new[75]	_	_
14-29	1620-1625	novel	abstract[75]|substance[76]	new[75]|giv[76]	coref	15-17[0_76]
14-30	1626-1637	antibiotics	abstract[75]|substance[76]	new[75]|giv[76]	_	_
14-31	1638-1639	.	_	_	_	_

#Text=The financial outcome of the development of life style drugs is much better than that of antibiotics .
15-1	1640-1643	The	abstract[77]	new[77]	_	_
15-2	1644-1653	financial	abstract[77]	new[77]	_	_
15-3	1654-1661	outcome	abstract[77]	new[77]	_	_
15-4	1662-1664	of	abstract[77]	new[77]	_	_
15-5	1665-1668	the	abstract[77]|event[78]	new[77]|new[78]	_	_
15-6	1669-1680	development	abstract[77]|event[78]	new[77]|new[78]	_	_
15-7	1681-1683	of	abstract[77]|event[78]	new[77]|new[78]	_	_
15-8	1684-1688	life	abstract[77]|event[78]|abstract[79]|substance[80]	new[77]|new[78]|new[79]|new[80]	coref	28-9[148_80]
15-9	1689-1694	style	abstract[77]|event[78]|abstract[79]|substance[80]	new[77]|new[78]|new[79]|new[80]	_	_
15-10	1695-1700	drugs	abstract[77]|event[78]|substance[80]	new[77]|new[78]|new[80]	_	_
15-11	1701-1703	is	_	_	_	_
15-12	1704-1708	much	_	_	_	_
15-13	1709-1715	better	_	_	_	_
15-14	1716-1720	than	_	_	_	_
15-15	1721-1725	that	_	_	_	_
15-16	1726-1728	of	_	_	_	_
15-17	1729-1740	antibiotics	substance	giv	coref	16-1
15-18	1741-1742	.	_	_	_	_

#Text=Antibiotics have to be cheap for a use in low-income or developing countries .
16-1	1743-1754	Antibiotics	substance	giv	coref	17-7[86_0]
16-2	1755-1759	have	_	_	_	_
16-3	1760-1762	to	_	_	_	_
16-4	1763-1765	be	_	_	_	_
16-5	1766-1771	cheap	_	_	_	_
16-6	1772-1775	for	_	_	_	_
16-7	1776-1777	a	abstract[83]	new[83]	coref	24-6[125_83]
16-8	1778-1781	use	abstract[83]	new[83]	_	_
16-9	1782-1784	in	abstract[83]	new[83]	_	_
16-10	1785-1795	low-income	abstract[83]|place[84]	new[83]|giv[84]	_	_
16-11	1796-1798	or	abstract[83]|place[84]	new[83]|giv[84]	_	_
16-12	1799-1809	developing	abstract[83]|place[84]	new[83]|giv[84]	_	_
16-13	1810-1819	countries	abstract[83]|place[84]	new[83]|giv[84]	_	_
16-14	1820-1821	.	_	_	_	_

#Text=Innovative but vague approaches to find novel antibiotics have been an influencing of the bacterial gene expression to modify the bacterial metabolism .
17-1	1822-1832	Innovative	abstract[85]	new[85]	coref	17-11[87_85]
17-2	1833-1836	but	abstract[85]	new[85]	_	_
17-3	1837-1842	vague	abstract[85]	new[85]	_	_
17-4	1843-1853	approaches	abstract[85]	new[85]	_	_
17-5	1854-1856	to	abstract[85]	new[85]	_	_
17-6	1857-1861	find	abstract[85]	new[85]	_	_
17-7	1862-1867	novel	abstract[85]|substance[86]	new[85]|giv[86]	coref	20-7[107_86]
17-8	1868-1879	antibiotics	abstract[85]|substance[86]	new[85]|giv[86]	_	_
17-9	1880-1884	have	_	_	_	_
17-10	1885-1889	been	_	_	_	_
17-11	1890-1892	an	abstract[87]	giv[87]	_	_
17-12	1893-1904	influencing	abstract[87]	giv[87]	_	_
17-13	1905-1907	of	abstract[87]	giv[87]	_	_
17-14	1908-1911	the	abstract[87]|abstract[89]	giv[87]|new[89]	coref	19-4[97_89]
17-15	1912-1921	bacterial	abstract[87]|abstract[89]	giv[87]|new[89]	_	_
17-16	1922-1926	gene	abstract[87]|abstract|abstract[89]	giv[87]|new|new[89]	coref	19-4
17-17	1927-1937	expression	abstract[87]|abstract[89]	giv[87]|new[89]	_	_
17-18	1938-1940	to	abstract[87]	giv[87]	_	_
17-19	1941-1947	modify	abstract[87]	giv[87]	_	_
17-20	1948-1951	the	abstract[87]|abstract[90]	giv[87]|new[90]	coref	18-1[91_90]
17-21	1952-1961	bacterial	abstract[87]|abstract[90]	giv[87]|new[90]	_	_
17-22	1962-1972	metabolism	abstract[87]|abstract[90]	giv[87]|new[90]	_	_
17-23	1973-1974	.	_	_	_	_

#Text=Such a modified metabolism might lead to novel metabolic products which have to be identified and tested for their antibacterial properties .
18-1	1975-1979	Such	abstract[91]	giv[91]	_	_
18-2	1980-1981	a	abstract[91]	giv[91]	_	_
18-3	1982-1990	modified	abstract[91]	giv[91]	_	_
18-4	1991-2001	metabolism	abstract[91]	giv[91]	_	_
18-5	2002-2007	might	_	_	_	_
18-6	2008-2012	lead	_	_	_	_
18-7	2013-2015	to	_	_	_	_
18-8	2016-2021	novel	substance[92]	new[92]	ana	18-19[0_92]
18-9	2022-2031	metabolic	substance[92]	new[92]	_	_
18-10	2032-2040	products	substance[92]	new[92]	_	_
18-11	2041-2046	which	substance[92]	new[92]	_	_
18-12	2047-2051	have	substance[92]	new[92]	_	_
18-13	2052-2054	to	substance[92]	new[92]	_	_
18-14	2055-2057	be	substance[92]	new[92]	_	_
18-15	2058-2068	identified	substance[92]	new[92]	_	_
18-16	2069-2072	and	substance[92]	new[92]	_	_
18-17	2073-2079	tested	substance[92]	new[92]	_	_
18-18	2080-2083	for	_	_	_	_
18-19	2084-2089	their	substance|abstract[94]	giv|new[94]	coref	24-3[124_94]
18-20	2090-2103	antibacterial	abstract[94]	new[94]	_	_
18-21	2104-2114	properties	abstract[94]	new[94]	_	_
18-22	2115-2116	.	_	_	_	_

#Text=Methods to alter gene expression may be varied growth conditions or a microbial co-culturing of various bacteria or of fungi and bacteria .
19-1	2117-2124	Methods	abstract[95]	new[95]	coref	19-8[99_95]
19-2	2125-2127	to	abstract[95]	new[95]	_	_
19-3	2128-2133	alter	abstract[95]	new[95]	_	_
19-4	2134-2138	gene	abstract[95]|abstract|abstract[97]	new[95]|giv|giv[97]	_	_
19-5	2139-2149	expression	abstract[95]|abstract[97]	new[95]|giv[97]	_	_
19-6	2150-2153	may	_	_	_	_
19-7	2154-2156	be	_	_	_	_
19-8	2157-2163	varied	abstract[99]|abstract[100]	giv[99]|giv[100]	coref	19-8[100_99]
19-9	2164-2170	growth	abstract|abstract[99]|abstract[100]	new|giv[99]|giv[100]	_	_
19-10	2171-2181	conditions	abstract[99]|abstract[100]	giv[99]|giv[100]	_	_
19-11	2182-2184	or	abstract[100]	giv[100]	_	_
19-12	2185-2186	a	abstract[100]|abstract[101]	giv[100]|new[101]	_	_
19-13	2187-2196	microbial	abstract[100]|abstract[101]	giv[100]|new[101]	_	_
19-14	2197-2209	co-culturing	abstract[100]|abstract[101]	giv[100]|new[101]	_	_
19-15	2210-2212	of	abstract[100]|abstract[101]	giv[100]|new[101]	_	_
19-16	2213-2220	various	abstract[100]|abstract[101]|animal[102]	giv[100]|new[101]|giv[102]	coref	19-22[0_102]
19-17	2221-2229	bacteria	abstract[100]|abstract[101]|animal[102]	giv[100]|new[101]|giv[102]	_	_
19-18	2230-2232	or	_	_	_	_
19-19	2233-2235	of	_	_	_	_
19-20	2236-2241	fungi	plant	new	_	_
19-21	2242-2245	and	_	_	_	_
19-22	2246-2254	bacteria	animal	giv	coref	31-8[164_0]
19-23	2255-2256	.	_	_	_	_

#Text=Other sources for the identification of novel antibiotics have been plants , marine invertebrates and insects or amphibia .
20-1	2257-2262	Other	substance[105]	giv[105]	coref	20-11[0_105]
20-2	2263-2270	sources	substance[105]	giv[105]	_	_
20-3	2271-2274	for	substance[105]	giv[105]	_	_
20-4	2275-2278	the	substance[105]|abstract[106]	giv[105]|new[106]	_	_
20-5	2279-2293	identification	substance[105]|abstract[106]	giv[105]|new[106]	_	_
20-6	2294-2296	of	substance[105]|abstract[106]	giv[105]|new[106]	_	_
20-7	2297-2302	novel	substance[105]|abstract[106]|substance[107]	giv[105]|new[106]|giv[107]	coref	28-4[146_107]
20-8	2303-2314	antibiotics	substance[105]|abstract[106]|substance[107]	giv[105]|new[106]|giv[107]	_	_
20-9	2315-2319	have	_	_	_	_
20-10	2320-2324	been	_	_	_	_
20-11	2325-2331	plants	substance|substance[109]	giv|giv[109]	coref|coref	20-11[109_0]|21-5[114_109]
20-12	2332-2333	,	substance[109]	giv[109]	_	_
20-13	2334-2340	marine	substance[109]|animal[110]	giv[109]|new[110]	_	_
20-14	2341-2354	invertebrates	substance[109]|animal[110]	giv[109]|new[110]	_	_
20-15	2355-2358	and	substance[109]	giv[109]	_	_
20-16	2359-2366	insects	substance[109]|animal	giv[109]|new	_	_
20-17	2367-2369	or	substance[109]	giv[109]	_	_
20-18	2370-2378	amphibia	substance[109]|animal	giv[109]|new	_	_
20-19	2379-2380	.	_	_	_	_

#Text=Isolated antimicrobial peptides from such sources have long been favored .
21-1	2381-2389	Isolated	substance[113]	new[113]	coref	24-19[127_113]
21-2	2390-2403	antimicrobial	substance[113]	new[113]	_	_
21-3	2404-2412	peptides	substance[113]	new[113]	_	_
21-4	2413-2417	from	substance[113]	new[113]	_	_
21-5	2418-2422	such	substance[113]|substance[114]	new[113]|giv[114]	ana	22-3[0_114]
21-6	2423-2430	sources	substance[113]|substance[114]	new[113]|giv[114]	_	_
21-7	2431-2435	have	_	_	_	_
21-8	2436-2440	long	_	_	_	_
21-9	2441-2445	been	_	_	_	_
21-10	2446-2453	favored	_	_	_	_
21-11	2454-2455	.	_	_	_	_

#Text=However , they still hamper with various problems like proteolytic instability , short in vivo half-lives , insufficient solubility and a poor bioavailability .
22-1	2456-2463	However	_	_	_	_
22-2	2464-2465	,	_	_	_	_
22-3	2466-2470	they	substance	giv	_	_
22-4	2471-2476	still	_	_	_	_
22-5	2477-2483	hamper	_	_	_	_
22-6	2484-2488	with	_	_	_	_
22-7	2489-2496	various	abstract[116]	new[116]	coref	24-16[126_116]
22-8	2497-2505	problems	abstract[116]	new[116]	_	_
22-9	2506-2510	like	abstract[116]	new[116]	_	_
22-10	2511-2522	proteolytic	abstract[116]|abstract[117]	new[116]|new[117]	_	_
22-11	2523-2534	instability	abstract[116]|abstract[117]	new[116]|new[117]	_	_
22-12	2535-2536	,	abstract[116]	new[116]	_	_
22-13	2537-2542	short	abstract[116]|abstract[119]	new[116]|new[119]	_	_
22-14	2543-2545	in	abstract[116]|abstract[119]	new[116]|new[119]	_	_
22-15	2546-2550	vivo	abstract[116]|abstract|abstract[119]	new[116]|new|new[119]	coref	32-18[176_0]
22-16	2551-2561	half-lives	abstract[116]|abstract[119]	new[116]|new[119]	_	_
22-17	2562-2563	,	abstract[116]	new[116]	_	_
22-18	2564-2576	insufficient	abstract[116]|substance[120]	new[116]|new[120]	_	_
22-19	2577-2587	solubility	abstract[116]|substance[120]	new[116]|new[120]	_	_
22-20	2588-2591	and	abstract[116]	new[116]	_	_
22-21	2592-2593	a	abstract[116]|abstract[121]	new[116]|new[121]	_	_
22-22	2594-2598	poor	abstract[116]|abstract[121]	new[116]|new[121]	_	_
22-23	2599-2614	bioavailability	abstract[116]|abstract[121]	new[116]|new[121]	_	_
22-24	2615-2616	.	_	_	_	_

#Text=Alternative small-molecule antibacterials are rare .
23-1	2617-2628	Alternative	substance[122]	giv[122]	ana	24-1[0_122]
23-2	2629-2643	small-molecule	substance[122]	giv[122]	_	_
23-3	2644-2658	antibacterials	substance[122]	giv[122]	_	_
23-4	2659-2662	are	_	_	_	_
23-5	2663-2667	rare	_	_	_	_
23-6	2668-2669	.	_	_	_	_

#Text=They own promising properties for an oral use , and are not expected to show problems reported for those antimicrobial peptides .
24-1	2670-2674	They	substance	giv	coref	25-3[128_0]
24-2	2675-2678	own	_	_	_	_
24-3	2679-2688	promising	abstract[124]	giv[124]	_	_
24-4	2689-2699	properties	abstract[124]	giv[124]	_	_
24-5	2700-2703	for	abstract[124]	giv[124]	_	_
24-6	2704-2706	an	abstract[124]|abstract[125]	giv[124]|giv[125]	_	_
24-7	2707-2711	oral	abstract[124]|abstract[125]	giv[124]|giv[125]	_	_
24-8	2712-2715	use	abstract[124]|abstract[125]	giv[124]|giv[125]	_	_
24-9	2716-2717	,	_	_	_	_
24-10	2718-2721	and	_	_	_	_
24-11	2722-2725	are	_	_	_	_
24-12	2726-2729	not	_	_	_	_
24-13	2730-2738	expected	_	_	_	_
24-14	2739-2741	to	_	_	_	_
24-15	2742-2746	show	_	_	_	_
24-16	2747-2755	problems	abstract[126]	giv[126]	_	_
24-17	2756-2764	reported	abstract[126]	giv[126]	_	_
24-18	2765-2768	for	abstract[126]	giv[126]	_	_
24-19	2769-2774	those	abstract[126]|substance[127]	giv[126]|giv[127]	_	_
24-20	2775-2788	antimicrobial	abstract[126]|substance[127]	giv[126]|giv[127]	_	_
24-21	2789-2797	peptides	abstract[126]|substance[127]	giv[126]|giv[127]	_	_
24-22	2798-2799	.	_	_	_	_

#Text=Presently , such small-molecule antibacterials that result from synthetic chemistry are unknown to emerge as a novel antibacterial compound class .
25-1	2800-2809	Presently	_	_	_	_
25-2	2810-2811	,	_	_	_	_
25-3	2812-2816	such	substance[128]	giv[128]	coref	26-10[135_128]
25-4	2817-2831	small-molecule	substance[128]	giv[128]	_	_
25-5	2832-2846	antibacterials	substance[128]	giv[128]	_	_
25-6	2847-2851	that	substance[128]	giv[128]	_	_
25-7	2852-2858	result	substance[128]|abstract	giv[128]|new	coref|none	32-11[175_0]|25-7[0_175]
25-8	2859-2863	from	substance[128]	giv[128]	_	_
25-9	2864-2873	synthetic	substance[128]|abstract[129]	giv[128]|new[129]	_	_
25-10	2874-2883	chemistry	substance[128]|abstract[129]	giv[128]|new[129]	_	_
25-11	2884-2887	are	_	_	_	_
25-12	2888-2895	unknown	_	_	_	_
25-13	2896-2898	to	_	_	_	_
25-14	2899-2905	emerge	_	_	_	_
25-15	2906-2908	as	_	_	_	_
25-16	2909-2910	a	abstract[131]	new[131]	_	_
25-17	2911-2916	novel	abstract[131]	new[131]	_	_
25-18	2917-2930	antibacterial	substance[130]|abstract[131]	new[130]|new[131]	coref	31-3[0_130]
25-19	2931-2939	compound	substance[130]|abstract[131]	new[130]|new[131]	_	_
25-20	2940-2945	class	abstract[131]	new[131]	_	_
25-21	2946-2947	.	_	_	_	_

#Text=We gained access to two novel structurally-related classes of small-molecule antibacterials by the reaction of substituted indoles and thiophene dicarbaldehyde .
26-1	2948-2950	We	person	acc	ana	31-1
26-2	2951-2957	gained	_	_	_	_
26-3	2958-2964	access	abstract[133]	new[133]	_	_
26-4	2965-2967	to	abstract[133]	new[133]	_	_
26-5	2968-2971	two	abstract[133]|abstract[134]	new[133]|new[134]	coref	31-1[163_134]
26-6	2972-2977	novel	abstract[133]|abstract[134]	new[133]|new[134]	_	_
26-7	2978-2998	structurally-related	abstract[133]|abstract[134]	new[133]|new[134]	_	_
26-8	2999-3006	classes	abstract[133]|abstract[134]	new[133]|new[134]	_	_
26-9	3007-3009	of	abstract[133]|abstract[134]	new[133]|new[134]	_	_
26-10	3010-3024	small-molecule	abstract[133]|abstract[134]|substance[135]	new[133]|new[134]|giv[135]	_	_
26-11	3025-3039	antibacterials	abstract[133]|abstract[134]|substance[135]	new[133]|new[134]|giv[135]	_	_
26-12	3040-3042	by	_	_	_	_
26-13	3043-3046	the	event[136]	new[136]	_	_
26-14	3047-3055	reaction	event[136]	new[136]	_	_
26-15	3056-3058	of	event[136]	new[136]	_	_
26-16	3059-3070	substituted	event[136]|substance[137]|abstract[138]	new[136]|new[137]|new[138]	coref|coref	27-10[142_137]|27-10[143_138]
26-17	3071-3078	indoles	event[136]|substance[137]|abstract[138]	new[136]|new[137]|new[138]	_	_
26-18	3079-3082	and	event[136]|abstract[138]	new[136]|new[138]	_	_
26-19	3083-3092	thiophene	event[136]|abstract[138]|substance|organization[140]	new[136]|new[138]|new|new[140]	_	_
26-20	3093-3107	dicarbaldehyde	event[136]|abstract[138]|organization[140]	new[136]|new[138]|new[140]	_	_
26-21	3108-3109	.	_	_	_	_

#Text=Therefore , various composed hybrid molecules were yielded from those indoles and benzothiophene .
27-1	3110-3119	Therefore	_	_	_	_
27-2	3120-3121	,	_	_	_	_
27-3	3122-3129	various	substance[141]	new[141]	coref	28-1[145_141]
27-4	3130-3138	composed	substance[141]	new[141]	_	_
27-5	3139-3145	hybrid	substance[141]	new[141]	_	_
27-6	3146-3155	molecules	substance[141]	new[141]	_	_
27-7	3156-3160	were	_	_	_	_
27-8	3161-3168	yielded	_	_	_	_
27-9	3169-3173	from	_	_	_	_
27-10	3174-3179	those	substance[142]|abstract[143]	giv[142]|giv[143]	_	_
27-11	3180-3187	indoles	substance[142]|abstract[143]	giv[142]|giv[143]	_	_
27-12	3188-3191	and	abstract[143]	giv[143]	_	_
27-13	3192-3206	benzothiophene	abstract[143]|substance	giv[143]|new	_	_
27-14	3207-3208	.	_	_	_	_

#Text=Hybrid molecules of antimicrobial active antibiotics , or antifungal drugs have recently been reviewed .
28-1	3209-3215	Hybrid	substance[145]	giv[145]	_	_
28-2	3216-3225	molecules	substance[145]	giv[145]	_	_
28-3	3226-3228	of	substance[145]	giv[145]	_	_
28-4	3229-3242	antimicrobial	substance[145]|substance[146]|substance[147]	giv[145]|giv[146]|giv[147]	coref|coref	28-4[147_146]|29-4[150_147]
28-5	3243-3249	active	substance[145]|substance[146]|substance[147]	giv[145]|giv[146]|giv[147]	_	_
28-6	3250-3261	antibiotics	substance[145]|substance[146]|substance[147]	giv[145]|giv[146]|giv[147]	_	_
28-7	3262-3263	,	substance[145]|substance[147]	giv[145]|giv[147]	_	_
28-8	3264-3266	or	substance[145]|substance[147]	giv[145]|giv[147]	_	_
28-9	3267-3277	antifungal	substance[145]|substance[147]|substance[148]	giv[145]|giv[147]|giv[148]	ana	29-1[0_148]
28-10	3278-3283	drugs	substance[145]|substance[147]|substance[148]	giv[145]|giv[147]|giv[148]	_	_
28-11	3284-3288	have	_	_	_	_
28-12	3289-3297	recently	_	_	_	_
28-13	3298-3302	been	_	_	_	_
28-14	3303-3311	reviewed	_	_	_	_
28-15	3312-3313	.	_	_	_	_

#Text=They mostly consist either of two different antibiotics or antifungals that are connected by a linker like a simple carbon chain .
29-1	3314-3318	They	substance	giv	_	_
29-2	3319-3325	mostly	_	_	_	_
29-3	3326-3333	consist	_	_	_	_
29-4	3334-3340	either	substance[150]|substance[151]	giv[150]|giv[151]	coref	29-4[151_150]
29-5	3341-3343	of	substance[150]|substance[151]	giv[150]|giv[151]	_	_
29-6	3344-3347	two	substance[150]|substance[151]	giv[150]|giv[151]	_	_
29-7	3348-3357	different	substance[150]|substance[151]	giv[150]|giv[151]	_	_
29-8	3358-3369	antibiotics	substance[150]|substance[151]	giv[150]|giv[151]	_	_
29-9	3370-3372	or	substance[151]	giv[151]	_	_
29-10	3373-3384	antifungals	substance[151]|substance[152]	giv[151]|new[152]	_	_
29-11	3385-3389	that	substance[151]|substance[152]	giv[151]|new[152]	_	_
29-12	3390-3393	are	substance[151]|substance[152]	giv[151]|new[152]	_	_
29-13	3394-3403	connected	substance[151]|substance[152]	giv[151]|new[152]	_	_
29-14	3404-3406	by	substance[151]|substance[152]	giv[151]|new[152]	_	_
29-15	3407-3408	a	substance[151]|substance[152]|object[153]	giv[151]|new[152]|new[153]	_	_
29-16	3409-3415	linker	substance[151]|substance[152]|object[153]	giv[151]|new[152]|new[153]	_	_
29-17	3416-3420	like	substance[151]|substance[152]|object[153]	giv[151]|new[152]|new[153]	_	_
29-18	3421-3422	a	substance[151]|substance[152]|object[153]|object[155]	giv[151]|new[152]|new[153]|new[155]	_	_
29-19	3423-3429	simple	substance[151]|substance[152]|object[153]|object[155]	giv[151]|new[152]|new[153]|new[155]	_	_
29-20	3430-3436	carbon	substance[151]|substance[152]|object[153]|substance|object[155]	giv[151]|new[152]|new[153]|new|new[155]	_	_
29-21	3437-3442	chain	substance[151]|substance[152]|object[153]|object[155]	giv[151]|new[152]|new[153]|new[155]	_	_
29-22	3443-3444	.	_	_	_	_

#Text=So fluoroquinolone-oxazolidinone hybrids reached clinical trials and novel 1 , 2 , 3-triazole antifungal hybrids with 8-aminoquinoline or dioxolane have recently been reported .
30-1	3445-3447	So	_	_	_	_
30-2	3448-3477	fluoroquinolone-oxazolidinone	abstract[156]	new[156]	coref	30-8[158_156]
30-3	3478-3485	hybrids	abstract[156]	new[156]	_	_
30-4	3486-3493	reached	_	_	_	_
30-5	3494-3502	clinical	event[157]	new[157]	_	_
30-6	3503-3509	trials	event[157]	new[157]	_	_
30-7	3510-3513	and	_	_	_	_
30-8	3514-3519	novel	abstract[158]	giv[158]	_	_
30-9	3520-3521	1	abstract[158]	giv[158]	_	_
30-10	3522-3523	,	abstract[158]	giv[158]	_	_
30-11	3524-3525	2	abstract[158]	giv[158]	_	_
30-12	3526-3527	,	abstract[158]	giv[158]	_	_
30-13	3528-3538	3-triazole	abstract[158]	giv[158]	_	_
30-14	3539-3549	antifungal	abstract[158]	giv[158]	_	_
30-15	3550-3557	hybrids	abstract[158]	giv[158]	_	_
30-16	3558-3562	with	abstract[158]	giv[158]	_	_
30-17	3563-3579	8-aminoquinoline	abstract[158]|abstract	giv[158]|new	_	_
30-18	3580-3582	or	abstract[158]	giv[158]	_	_
30-19	3583-3592	dioxolane	abstract[158]|object	giv[158]|new	_	_
30-20	3593-3597	have	_	_	_	_
30-21	3598-3606	recently	_	_	_	_
30-22	3607-3611	been	_	_	_	_
30-23	3612-3620	reported	_	_	_	_
30-24	3621-3622	.	_	_	_	_

#Text=Our novel compound classes were tested against prominent Gram-positive bacteria that are associated with severe hospital infections by Staphylococcus and Enterococcus strains .
31-1	3623-3626	Our	person|abstract[163]	giv|giv[163]	ana	32-1
31-2	3627-3632	novel	abstract[163]	giv[163]	_	_
31-3	3633-3641	compound	substance|abstract[163]	giv|giv[163]	_	_
31-4	3642-3649	classes	abstract[163]	giv[163]	_	_
31-5	3650-3654	were	_	_	_	_
31-6	3655-3661	tested	_	_	_	_
31-7	3662-3669	against	_	_	_	_
31-8	3670-3679	prominent	animal[164]	giv[164]	_	_
31-9	3680-3693	Gram-positive	animal[164]	giv[164]	_	_
31-10	3694-3702	bacteria	animal[164]	giv[164]	_	_
31-11	3703-3707	that	animal[164]	giv[164]	_	_
31-12	3708-3711	are	animal[164]	giv[164]	_	_
31-13	3712-3722	associated	animal[164]	giv[164]	_	_
31-14	3723-3727	with	animal[164]	giv[164]	_	_
31-15	3728-3734	severe	animal[164]|event[166]	giv[164]|new[166]	_	_
31-16	3735-3743	hospital	animal[164]|place|event[166]	giv[164]|new|new[166]	_	_
31-17	3744-3754	infections	animal[164]|event[166]	giv[164]|new[166]	_	_
31-18	3755-3757	by	animal[164]|event[166]	giv[164]|new[166]	_	_
31-19	3758-3772	Staphylococcus	animal[164]|event[166]|animal|abstract[169]	giv[164]|new[166]|giv|new[169]	_	_
31-20	3773-3776	and	animal[164]|event[166]|abstract[169]	giv[164]|new[166]|new[169]	_	_
31-21	3777-3789	Enterococcus	animal[164]|event[166]|abstract|abstract[169]	giv[164]|new[166]|new|new[169]	_	_
31-22	3790-3797	strains	animal[164]|event[166]|abstract[169]	giv[164]|new[166]|new[169]	_	_
31-23	3798-3799	.	_	_	_	_

#Text=We identified first lead compounds with promising activities and confirmed the in vitro results first in the in vivo studies for selected derivatives .
32-1	3800-3802	We	person	giv	_	_
32-2	3803-3813	identified	_	_	_	_
32-3	3814-3819	first	substance[172]	new[172]	_	_
32-4	3820-3824	lead	person|substance[172]	new|new[172]	_	_
32-5	3825-3834	compounds	substance[172]	new[172]	_	_
32-6	3835-3839	with	substance[172]	new[172]	_	_
32-7	3840-3849	promising	substance[172]|abstract[173]	new[172]|new[173]	_	_
32-8	3850-3860	activities	substance[172]|abstract[173]	new[172]|new[173]	_	_
32-9	3861-3864	and	_	_	_	_
32-10	3865-3874	confirmed	_	_	_	_
32-11	3875-3878	the	abstract[175]	new[175]	_	_
32-12	3879-3881	in	organization[174]|abstract[175]	new[174]|new[175]	_	_
32-13	3882-3887	vitro	organization[174]|abstract[175]	new[174]|new[175]	_	_
32-14	3888-3895	results	abstract[175]	new[175]	_	_
32-15	3896-3901	first	_	_	_	_
32-16	3902-3904	in	_	_	_	_
32-17	3905-3908	the	abstract[177]	new[177]	_	_
32-18	3909-3911	in	abstract[176]|abstract[177]	giv[176]|new[177]	_	_
32-19	3912-3916	vivo	abstract[176]|abstract[177]	giv[176]|new[177]	_	_
32-20	3917-3924	studies	abstract[177]	new[177]	_	_
32-21	3925-3928	for	abstract[177]	new[177]	_	_
32-22	3929-3937	selected	abstract[177]|substance[178]	new[177]|new[178]	_	_
32-23	3938-3949	derivatives	abstract[177]|substance[178]	new[177]|new[178]	_	_
32-24	3950-3951	.	_	_	_	_
